AMIX (37) CODX (37) ICCM (46) NVNO (50) ⌘ Pro Terminal →

Beyond Air Inc. (XAIR) — RQD Stock Rating Cockpit

$2.31 -2.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Beyond Air Inc. (XAIR) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $3.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XAIR)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

39.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $2$2.31H: $53

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on XAIR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 3.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

12/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like XAIR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Priced at 112x earnings—high expectations leave less room for a lukewarm quarter.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XAIR)

✓Walkthrough of XAIR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XAIR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.00%▼ DESCENDING CHANNEL

2026-10-30O $2.28H $2.39L $2.24C $2.31VOL 12.3K

RES: $3.38SUP: $0.80SMA50: $3.04SMA200: $10.47

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XAIR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XAIR Butterfly Map → + Track XAIR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +107.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XAIR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XAIR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XAIR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XAIR)

Health Care Rank #599 of 1016 ⚔️ AMIX vs XAIR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XAIR vs. AMIX, CODX, ICCM, NVNO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Beyond Air Inc. (XAIR) ranks #599 by composite RQD confidence (42/100, grade D-) and #965 by equity capitalization ($3.8M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while XAIR leads on capital efficiency and profitability with -35.0% ROIC and 3.3% gross margin. NVNO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with XAIR at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XAIR ACTIVE Beyond Air Inc.	D-	42/100	112.1x	3.3%	-35.0%	-2.12%	$3.8M	Benchmark Subject
AMIX Autonomix Medical Inc.	D-	37/100	—	—	-35.0%	-5.12%	$4.0M	/amix-vs-xair →
CODX Co-Diagnostics Inc.	D-	37/100	—	64.3%	-35.0%	-10.49%	$3.5M	/codx-vs-xair →
ICCM IceCure Medical Ltd.	D	46/100	—	36.3%	-35.0%	-2.13%	$3.3M	/iccm-vs-xair →
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-xair →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001641631

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Beyond Air Inc. (XAIR) reported GAAP revenue of $7.7M (+107.3% vs. FY2024 revenue of $3.7M , and +562.6% cumulative change since FY2023) , GAAP net income of $34.3K, operating cash flow of -$18.1M, and free cash flow of -$19.2M (+56.5% YoY). On the balance sheet, XAIR closed FY2025 with $36.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$7.7M	$34.3K	-$18.1M	-$19.2M	$36.8M	—
FY2024 (FY)	2025-03-31	$3.7M	$48.5K	-$38.2M	-$44.1M	$34.1M	—
FY2023 (FY)	2024-03-31	$1.2M	$64.3K	-$56.0M	-$56.0M	—	—

3. XAIR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XAIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Beyond Air Inc. (NASDAQ: XAIR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.31 (-2.12% 1D, market cap $3.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XAIR ranks #599 in composite RQD confidence.

How does XAIR compare to AMIX and CODX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), XAIR carries a Roarable D- (42/100 RQD), trailing P/E of 112.1x, gross margin of 3.3%, and ROIC of -35.0%. By comparison, AMIX (Autonomix Medical Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and CODX (Co-Diagnostics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while XAIR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XAIR?

Per XAIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001641631), Beyond Air Inc. generated $7.7M in revenue (+107.3% YoY), $34.3K in net income, and -$19.2M in free cash flow against $36.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XAIR trading relative to its 50-day, 200-day, and 52-week technical levels?

XAIR last traded at $2.31 (-2.12% on volume of 16,530 shares), positioning the stock -24.01% below its 50-day simple moving average ($3.04) and -77.94% below its 200-day simple moving average ($10.47). Across its 52-week range of $2.05 to $53.20, XAIR sits at the 0.5% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.02 to $2.60).

XAIR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell XAIR stock right now?

Beyond Air Inc. (XAIR) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at 112x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.

What is XAIR's 12-month price target and RQD AI Jury consensus?

XAIR's 12-month base price target is $2.14 (range $1.67 to $55.86), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: XAIR RQD Cockpit XAIR 12M Forecast XAIR Earnings & Move XAIR Dividends & DRIP XAIR Insiders & 13F XAIR Whale Options XAIR Profit Sankey XAIR News & Why